Kanglevax R&D grew by 30% YoY in the first half of the year, and several HPV vaccines achieved positive clinical results.

On August 30, Kanglevax (833575) announced its 2024 half-year report. The data showed that the Company achieved operating income of RMB373,000 in the first half of 2024, down 55.55% YoY; the net profit attributable to the parent was RMB-185 million, down 29.49% YoY, and the Company's R&D expenses were RMB136 million, up 30.01% YoY. Notably, the Company obtained the notice of the China Securities Regulatory Commission on its overseas listing in July 2024. During the reporting period, the III phase clinical trials of three-valent HPV vaccine, nine-valent HPV vaccine (female indication) and nine-valent HPV vaccine (male indication) were carried out as scheduled, and the fifteen-valent HPV vaccine entered the I phase clinical trial in March this year, which was conducted by Chengda Biological for the subsequent clinical trials. The in-process pipeline products, two-valent respiratory syncytial virus vaccine and shingles vaccine, are expected to submit IND application in 2024; seven-valent norovirus vaccine and mRNA two-valent therapeutic HPV vaccine are expected to submit IND in 2025; and four-valent hand, foot and mouth disease vaccine is expected to submit IND after 2025. In terms of industrialization, Kanglevax said that its Kunming production base obtained the drug production license in August 2024, which can ensure the Company's products can be immediately put into commercial production after obtaining the BLA approval, with a planned annual capacity of 10 million doses of three-valent HPV vaccine and 30 million doses of nine-valent HPV vaccine.